Matthew Goetz, MD

Articles

Dr Goetz on the Early Pharmacokinetic Data With Neoadjuvant (Z)-endoxifen in ER+/HER2– Breast Cancer

April 11th 2024

Matthew P. Goetz, MD, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen in estrogen receptor–positive, HER2-negative breast cancer.

Dr Goetz on Post-CDK4/6 Inhibitor Treatment Options in HR-Positive Breast Cancer

August 25th 2023

Matthew P. Goetz, MD, discusses the available treatment options for patients with metastatic hormone receptor–positive breast cancer in the post-CDK inhibitor setting.

Dr. Goetz on the Clinical Significance of Lasofoxifene in ER+/HER2- Breast Cancer

October 7th 2022

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

Dr. Goetz on the ELAINE-1 Trial of Lasofoxifene in ESR1-Mutated, ER+/HER2- Breast Cancer

September 19th 2022

Matthew P. Goetz, MD, discusses the progression-free survival benefit derived with lasofoxifene in patients with ESR1-mutated, ER-positive/ HER2-negative metastatic breast cancer.

Dr. Goetz on Adjuvant Capecitabine Following Neoadjuvant Chemotherapy and Surgery

December 10th 2015

Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, andprofessor of Pharmacology at Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.